Kenneth Galbraith serves as the Chair, President, and CEO of ZYMEWORKS INC, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel biotherapeutics. With a robust background in the biopharmaceutical industry, Galbraith has been instrumental in steering ZYMEWORKS towards significant milestones in its journey to innovate cancer treatments. His leadership has been pivotal in advancing the company's proprietary Azymetric™ and Efymetric™ platforms, which are designed to enhance the therapeutic potential of antibodies and other biologics. Before joining ZYMEWORKS, Galbraith held various leadership positions within the biopharmaceutical sector, accumulating over two decades of experience. He previously served as the Chief Operating Officer at Celator Pharmaceuticals, where he played a key role in the development and eventual FDA approval of the company's flagship product, Vyxeos®. This experience has equipped him with a deep understanding of the complexities involved in bringing novel therapeutics from the lab to the market. At ZYMEWORKS, Galbraith's strategic vision has been crucial in forging partnerships with major pharmaceutical companies, securing funding, and expanding the company's research and development capabilities. Under Galbraith's leadership, ZYMEWORKS has made significant strides in its clinical programs, particularly in the field of oncology. His commitment to advancing science and improving patient outcomes is evident in the company's robust pipeline, which includes multiple candidates in various stages of clinical trials. Galbraith's role extends beyond operational oversight; he is also a key figure in shaping the company's culture, fostering an environment of innovation and collaboration. His contributions have not only positioned ZYMEWORKS as a leader in biotherapeutic development but have also earned him recognition within the industry as a visionary leader dedicated to transforming cancer care.